Tularik is headquartered in San Francisco, California.
Tularik has 406 employees.
Tularik is a life science company.
Tularik was founded in 1991.
1120 Veterans Boulevard,
San Francisco, California
94080
United States,
(650) 825-7000
www.tularik.com
Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. Tularik currently has five drug candidates in clinical trials. In the cancer area, Tularik is currently conducting a pivotal study of T67 for the treatment of hepatocellular carcinoma and Phase 2 trials with T607 for the treatment of gastric and esophageal cancer. T487, for the treatment of inflammatory diseases, and T131, for the treatment of type 2 diabetes, are in Phase 2 trials to evaluate safety and pharmacokinetic parameters.
| Year | ≤ '92 | '93 | '94 | '95 | '96 | '97 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.2/yr) | # | - | - | - | - | - | 1 | 1 |
| Sell (0.0/yr) | # | - | - | - | - | - | - | 0 |
| 1 | ||||||||
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
